Telik (TELK) Resumes Trading, Up 73%
Telik Inc. (NASDAQ: TELK) has resumed trading following the volatility trading halt and is now up 73% to $2.51. The company was granted orphan drug status for Telintra for myelodysplastic syndrome.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Pro Diversity Network (IPDN) halted for second time on LUDP; Last up 63%
- Galectin Therapeutics (GALT) sinks 39% as trading resumes
- Cosi (COSI) Files for Chapter 11 Bankruptcy
Create E-mail Alert Related CategoriesTrading Halts
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!